How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries
Anna Kemp A E , David B. Preen A , John Glover B , James Semmens C and Elizabeth E. Roughead DA Centre for Health Services Research, School of Population Health, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. Email: david.preen@uwa.edu.au
B Population Health Information Development Unit, University of Adelaide, Adelaide, SA 5001, Australia. Email: john.glover@adelaide.edu.au
C Curtin Health Innovation Research Institute (CHIRI), Centre for Population Health Research, Curtin University, GPO Box U1987, Perth, WA 6845, Australia. Email: james.semmens@curtin.edu.au
D Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia. Email: libby.roughead@unisa.edu.au
E Corresponding author. Email: anna.kemp@uwa.edu.au
Australian Health Review 35(3) 341-349 https://doi.org/10.1071/AH10906
Submitted: 8 April 2010 Accepted: 28 October 2010 Published: 25 August 2011
Journal Compilation © AHHA 2011
Abstract
Objectives. To determine changes in out-of-pocket expenditure on prescription medicines for Australian patients, and how patient expenditure compares with other Organisation for Economic Co-operation and Development (OECD) countries.
Methods. We examined out-of-pocket expenditure on prescription medicines by patients in Australia between 1970 and 2007, and between Australia and 15 other OECD countries (Canada, Czech Republic, Denmark, Finland, France, Germany, Japan, Republic of Korea (South Korea), Luxembourg, Poland, Slovak Republic, Spain, Sweden, Switzerland and the United States) in 2005.
Findings. Spending on publicly subsidised medicines by Australian patients increased from $16 per person in 1971 to $62 in 2007. Patient expenditure on all prescription medicines had risen to $134 per person in 2007. Out-of-pocket expenditure for Australian patients ranked 4th of 14 OCED countries with universal pharmaceutical subsidies. Australian patients pay 28% of national pharmaceutical expenditure; more than patients in South Korea (27%), Slovak Republic (26%), Sweden (22%), France, Luxembourg, Japan and Switzerland (17%), Germany (15%), Czech Republic (11%) and Spain (6%), but less than patients in Finland (36%), Denmark (33%) and Poland (34%).
Conclusions. Compared to other OECD countries, Australian out-of-pocket costs are now in the mid to upper range. Further increases have the potential to significantly affect access to care.
What is known about the topic? In Australia and internationally, increases in the portion of prescription medicines paid by patients have been associated with falls in utilisation. Despite the pharmaceutical subsidies patients receive under the Australian Pharmaceutical Benefits Scheme, prescription medicine costs are a barrier to access for many low income, elderly and other vulnerable patients.
What does this paper add? The findings demonstrate that the prescription medicine expenditure of Australian patients has increased substantially over recent years, and is double that indicated by benefit-paid data alone. Out-of-pocket expenditure in Australia is moderate-to-high by international standards.
What are the implications for practitioners? Patient out-of-pocket expenditure for prescription medicines in Australia has increased in recent decades, accounting for higher proportions of household and national medicine expenditure. Lack of patient involvement in treatment decisions is associated with patients forgoing medicines due to costs. Practitioners are encouraged to discuss treatment decisions, cost-barriers and possible strategies to overcome cost-barriers with their patients.
Additional keywords: international comparison, pharmaceutical expenditure, private expenditure.
References
[1] Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med 2007; 4 e283| Physician awareness of drug cost: a systematic review.Crossref | GoogleScholarGoogle Scholar |
[2] Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001; 16 793–9.
| Self-restriction of medications due to cost in seniors without prescription coverage.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD387mvF2hsA%3D%3D&md5=a2af8aaddbf8e06a8adc8dab9e5fed27CAS |
[3] Schoen C, Osborn R, Doty MM, Bishop M, Peugh J, Murukutla N. Toward higher-performance health systems: adults’ health care experiences in seven countries, 2007. Health Aff 2007; 26 w717–34.
| Toward higher-performance health systems: adults’ health care experiences in seven countries, 2007.Crossref | GoogleScholarGoogle Scholar |
[4] Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 89–103.
| European healthcare policies for controlling drug expenditure.Crossref | GoogleScholarGoogle Scholar |
[5] Rickard M. The Pharmaceutical Benefits Scheme: options for cost control. Canberra: Social Policy Group, Parliamentary Library; 2002. Current Issues Brief number 12 2001–02.
[6] Expenditure and prescriptions twelve months to 30 June 2008. Canberra: Australian Government Department of Health and Ageing; 2008.
[7] Doran E, Henry DA. The PBS community awareness campaign: how helpful is blaming patients? Med J Aust 2003; 179 544–5.
[8] Doran E, Henry D. Pharmaceutical benefits scheme policy: confused and tough on patients. Intern Med J 2006; 36 211–3.
| Pharmaceutical benefits scheme policy: confused and tough on patients.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD283jsVamtQ%3D%3D&md5=78cadd37755589d27bfd21703e9400b7CAS |
[9] Harvey K. Securing the future of the Pharmaceutical Benefits Scheme? Australian Review 2002. Available at http://www.australianreview.net/digest/2002/06/harvey.html [verified 8 April 2010].
[10] Schedule of Pharmaceutical Benefits, 31 July. Australian Government Department of Health and Ageing; 2010. Available at http://www.pbs.gov.au/html/healthpro/publication/view?date=20100401&type=FlashPaper&name=general-schedule [verified 8 April 2010].
[11] Hynd A, Roughead E, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment changes on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17 1091–9.
| The impact of co-payment changes on dispensings of government-subsidised medicines in Australia.Crossref | GoogleScholarGoogle Scholar |
[12] Doran E, Robertson J, Rolfe I, Henry D. Patient co-payments and use of prescription medicines. Aust N Z J Public Health 2004; 28 62–7.
| Patient co-payments and use of prescription medicines.Crossref | GoogleScholarGoogle Scholar |
[13] Health expenditure Australia 2004–05. Canberra: Australian Institute of Health and Welfare; 2006.
[14] Health expenditure Australia 2006–07. Canberra: Australian Institute of Health and Welfare; 2008.
[15] Interactive expenditure data. Canberra: Australian Institute of Health and Welfare; 2009. Available at http://www.aihw.gov.au/expenditure/datacubes/index.cfm [verified 8 April 2010].
[16] Health expenditure Australia 2002–03. Canberra: Australian Institute of Health and Welfare; 2004.
[17] OECD Health Data 2011. Organisation for Economic Co-operation and Development; 2011. Available at http://www.oecd.org/health/healthdata [verified 25 July 2011].
[18] Past copayments and Safety Net thresholds. Department of Health and Ageing; 2010. Available at http://www.aodgp.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pbs-copayment.htm [verified 8 April 2010].
[19] Johnston M. The price elasticity of demand for pharmaceuticals. In: Smith CS, editor. Economics and health 1990: proceedings of the Twelfth Australian Conference of Health Economists. Melbourne: Monash University and Fairfield Hospital; 1990: 22–43.
[20] Australia’s health 1994. Canberra: AGPS, Australian Institute of Health and Welfare; 1994. Available at http://www.aihw.gov.au/publications/aus/ah94/ah94.pdf [verified 8 April 2010].
[21] Australian Statistics on Medicines 1997. Canberra: Commonwealth Department of Health and Family Services, Drug Utilisation Sub Committee; 1998.
[22] Australia’s Health 2008. Canberra: Australian Institute of Health and Welfare; 2008.
[23] Australian Statistics on Medicines 2007. Canberra: Department of Health and Ageing, Drug Utilisation Sub Committee; 2009.
[24] Purchasing power parities for GDP and related indicators. Organisation for Economic Co-operation and Development; 2011. Available at http://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP [verified 25 July 2011].
[25] New GDP comparisons based on Purchasing Power Parities for the year 2002. Paris: Organisation for Economic Co-operation and Development; 2005. Available at http://www.oecd.org/dataoecd/32/62/34256773.pdf [verified 8 April 2010].
[26] 5206.0 – Australian National Accounts: National Income, Expenditure and Product, Mar 2011. Canberra: Australian Bureau of Statistics; 2011. http://www.abs.gov.au/Ausstats/abs@.nsf/mf/5206.0 [verified 8 April 2010].
[27] PBS Statistics. Canberra: Medicare Australia; 2009. Available at https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml [verified 13 February 2009].
[28] Schoen C, Osborn R, How SKH, Doty MM, Peugh J. In chronic condition: experiences of patients with complex health care needs, in eight countries, 2008. Health Aff 2009; 28 w1–16.
| In chronic condition: experiences of patients with complex health care needs, in eight countries, 2008.Crossref | GoogleScholarGoogle Scholar |
[29] Hynd A, Roughead E, Preen DB, Glover J, Bulsara M, Semmens J. Increased patient co-payments and changes in subsidised prescription medicines dispensed in Western Australia. Aust N Z J Public Health 2009; 33 246–52.
| Increased patient co-payments and changes in subsidised prescription medicines dispensed in Western Australia.Crossref | GoogleScholarGoogle Scholar |
[30] Paris V, Docteur E. Pharmaceutical pricing and reimbursement policies in Canada: Directorate for Employment, Labour and Social Affairs Health Committee; 2006.
[31] Davidova J, Praznovcova L, Lundborg CS. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. Pharm World Sci 2008; 30 57–64.
| Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.Crossref | GoogleScholarGoogle Scholar |
[32] Strandberg-Larsen M, Knudsen MS. ISPOR global health care systems road map: Denmark – Pharmaceuticals. International Society for Pharmacoeconomics and Outcomes Research; 2009. Available at http://www.ispor.org/htaroadmaps/denmark.asp [verified 25 July 2011].
[33] Rinta S. Pharmaceutical pricing and reimbursement in Finland. Eur J Health Econ 2001; 2 128–35.
| Pharmaceutical pricing and reimbursement in Finland.Crossref | GoogleScholarGoogle Scholar |
[34] Review of NHS prescription charges and exemption arrangements in Scotland: consultation. Edinburgh: Scottish Executive; 2006. Available at http://www.scotland.gov.uk/Resource/Doc/90909/0021837.pdf [verified 8 April 2010].
[35] le Polain M, Franken M, Koopmanschap M, Cleemput I. Drug reimbursement systems: international comparison and policy recommendations. Health Services Research (HSR), KCE Reports 147C. D/2010/10.273/90. Brussels: Belgian Healthcare Knowledge Centre (KCE); 2010.
[36] The OECD Health Project: Private health insurance in OECD countries. Paris: Organisation for Economic Co-operation and Development; 2004.
[37] Sandier S, Paris V, Polton D, Thomson S, Mossialos E. Health care systems in transition: France. European Observatory on Health Care Systems; 2004. Available at http://www.euro.who.int/document/e83126.pdf [verified 8 April 2010].
[38] Health insurance and the electronic health card. Federal German Ministry for Health; 2005. Available at http://www.beyondpoverty.re.kr/share/download.jsp?bbsid=3&seq=270&fseq=1 [verified 8 April 2010].
[39] Health care systems in transition. Luxembourg: European Observatory on Health Care Systems; 1999. Available at http://www.euro.who.int/document/e67498.pdf [verified 8 April 2010].
[40] Kuszewski K, Gericke C. Health Systems in Transition: Poland. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2005. Available at http://www.euro.who.int/__data/assets/pdf_file/0011/95159/E88670.pdf [verified 25 July 2011].
[41] Review of prescription charges in Western Europe, North American and Australasia. Edinburgh: Scottish Executive; 2006. Available at http://www.scotland.gov.uk/Resource/Doc/92240/0022048.pdf [verified 8 April 2010].
[42] Moise P, Docteur E. Pharmaceutical pricing and reimbursement policies in Sweden. Directorate for Employment, Labour and Social Affairs Health Committee; 2007.
